Key Developments: Tianyin Pharmaceutical Co Inc (TPI)

TPI on American Stock Exchange

5 May 2015
Change (% chg)

$0.01 (+2.04%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Tianyin Pharmaceutical Co Inc to form strategic alliance with Buchang Pharma
Wednesday, 14 Jan 2015 11:26am EST 

Tianyin Pharmaceutical Co Inc and Buchang Pharmaceutical Co Ltd:Plan to establish Tianyin-Buchang Strategic Alliance to synergize and accelerate the growth of the Company, boosting TPI's mTCM franchise focusing on its cardiovascular revenue driver Gingko Mihuan.King & Wood Mallesons participated as an advisor to the establishment of the Alliance.  Full Article

Tianyin Pharmaceutical Co Inc announces CFO resignation - Form 8-K
Tuesday, 6 Jan 2015 04:50pm EST 

Tianyin Pharmaceutical Co Inc:Says on Dec. 31, 2014, James Tong, chief financial officer (CFO) and director, tendered his resignation as the CFO and director.Says on Jan. 5, 2015, it accepted Tong’s resignation, effectively immediately.Says on the same day, it appointed Guoqing Jiang as acting CFO, effective immediately.  Full Article

Tianyin Pharmaceutical Co Inc lowers FY 2014 revenue guidance
Thursday, 15 May 2014 08:53am EDT 

Tianyin Pharmaceutical Co Inc:Revises FY 2014 previous revenue forecast of 0 pct to 5 pct growth year over year to (20-30) pct year over year reduction mainly due to the further underperformance of generic segment and the rippling market impact from the Hugan Tablets incident.  Full Article

Tianyin Pharmaceutical Co Inc reaffirms FY 2013 revenue guidance
Friday, 14 Feb 2014 12:50am EST 

Tianyin Pharmaceutical Co Inc:Says it reiterate the revenue forecast to range from 0 pct to 5 pct year over year growth from fiscal 2013.Says the company reported revenue of $67.5 million in fiscal 2013.  Full Article

Tianyin Pharmaceutical Co Inc Announces Auditor Change Updates
Tuesday, 15 Oct 2013 12:23am EDT 

Tianyin Pharmaceutical Co Inc announced that as of October 8, 2013, the Audit Committee and the Board of Directors of TPI (the Company) both unanimously approved the termination of the Company's independent auditor, Patrizio and Zhao LLC (P&Z), due to the fact that P&Z agreed to a cease-and-desist order and prohibition from practicing before the Securities and Exchange Commission (the SEC) on September 30, 2013, with the right to apply for reinstatement after three years. engagement with P&Z on October 8, 2013, there were no: (1) disagreements with P&Z on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to their satisfaction, would have caused them to make reference in connection with their opinion to the subject matter of the disagreements, or (2) reportable events. Since P&Z is barred from practicing before the SEC, financial statements for a period previously audited by P&Z and required to be included in a filing made by the Company after September 30, 2013 will have to be re-audited by a firm that is registered with the PCAOB. Currently, the Company is evaluating options to appoint a new independent registered public accounting firm to replace P&Z.  Full Article

Tianyin Pharmaceutical Co Inc Issues FY 2014 Revenue Guidance
Friday, 27 Sep 2013 06:13am EDT 

Tianyin Pharmaceutical Co Inc announced that for fiscal 2014, it expects revenue growth to range from 0% to 5%. The Company reported revenue of $67.5 million in fiscal 2013.  Full Article

No consensus analysis data available.
Search Stocks